DTX1

DTX1 is a cytoplasmic E3 ubiquitin ligase that regulates Notch signaling and shapes cellular phenotype by directing substrate ubiquitination and degradation (PMID:29440432, PMID:11153911). On tubulovesicular recycling endosomes, DTX1 colocalizes with Notch1 and controls its endosomal sorting by ubiquitinating the lipid kinase PI5P4Kγ; loss of DTX1 enhances Rab4a-mediated Notch1 recycling and raises cell-surface Notch1 and signaling, while loss of PI5P4Kγ activity reduces Notch1 recycling, placing DTX1 upstream of receptor transport via control of PI(4,5)P2 production (PMID:29440432). Beyond Notch trafficking, DTX1 acts on a series of substrates whose degradation reprograms inflammatory and structural cell states: it ubiquitinates NLRP3 to promote its proteasomal degradation and suppress hepatocyte pyroptosis, with DTX1 itself transcriptionally activated by HNF4α (PMID:39319341); it degrades TUBB3 in Kupffer cells to block AKT signaling and suppress M2 polarization of tumor-associated macrophages (PMID:41577987); and it ubiquitinates ITGA5 at lysine 137 to maintain the contractile phenotype of vascular smooth muscle cells and attenuate aortic dissection (PMID:42090073). DTX1 also drives microglial M1 polarization and neuroinflammation through NF-κB/IRF5 signaling following traumatic brain injury (PMID:40660011).

1. 2000 Low

   Established the molecular identity of human DTX1 as a cytoplasmic protein positioned as a positive regulator of Notch signaling, providing the gene model on which later mechanistic work was built.

   Evidence genomic characterization, chromosomal mapping (12q24), and cDNA analysis

   PMID:11153911

   Open questions at the time

   • Functional annotation inferred from prior literature without direct mechanistic experiment in this study
   • No biochemical demonstration of E3 ligase activity
   • No substrate identified
2. 2018 High

   Resolved how DTX1 controls Notch1 signaling at the level of receptor trafficking, showing it restrains Notch1 recycling by ubiquitinating a lipid kinase on recycling endosomes rather than acting solely on the receptor.

   Evidence siRNA silencing, immunolocalization, ubiquitination substrate screen, Rab4a transport assays, and pharmacological inactivation of PI5P4Kγ

   PMID:29440432

   Open questions at the time

   • Whether DTX1 directly ubiquitinates Notch1 in addition to PI5P4Kγ not resolved here
   • Ubiquitination site(s) on PI5P4Kγ not mapped
   • Regulation of DTX1 recruitment to recycling endosomes unknown
3. 2024 Medium

   Extended DTX1 substrate repertoire to NLRP3, defining a degradative anti-inflammatory axis and placing DTX1 expression under HNF4α transcriptional control.

   Evidence reciprocal Co-IP, ubiquitination assay, luciferase reporter, and ChIP in a hepatocyte pyroptosis context

   PMID:39319341

   Open questions at the time

   • Ubiquitin chain type and degradation route not characterized
   • Single-lab study without independent replication
   • Direct vs indirect ubiquitination of NLRP3 not fully dissected
4. 2025 Medium

   Implicated DTX1 in driving proinflammatory microglial M1 polarization via NF-κB/IRF5 signaling after traumatic brain injury, linking it to neuroinflammatory phenotype switching.

   Evidence adenoviral overexpression and siRNA knockdown with cytokine/marker analysis in vitro and in a rat TBI model

   PMID:40660011

   Open questions at the time

   • Ubiquitination substrate underlying the NF-κB/IRF5 effect not identified
   • Direction opposite to the anti-inflammatory NLRP3 axis not mechanistically reconciled
   • Single-lab study
5. 2026 Medium

   Defined two further degradative substrate relationships—TUBB3 in Kupffer cells (suppressing AKT-driven macrophage M2 polarization) and ITGA5 at K137 in vascular smooth muscle cells (maintaining contractile phenotype)—broadening DTX1's role in tissue-specific phenotype control.

   Evidence Co-IP, ubiquitination assays with site mapping, gain/loss-of-function, and in vivo HCC and BAPN-induced aortic dissection models

   PMID:41577987 PMID:42090073

   Open questions at the time

   • Ubiquitin chain linkage types not defined for TUBB3
   • Whether substrate selectivity is governed by tissue-specific cofactors unknown
   • Single-lab studies for each substrate

• How DTX1 selects among its diverse substrates (PI5P4Kγ, NLRP3, TUBB3, ITGA5) across cell types, and how its opposing pro- and anti-inflammatory outputs are reconciled, remains unresolved.
• No unifying model for substrate recognition or adaptor requirement
• Structural basis of substrate engagement uncharacterized
• Cell-type determinants of opposing inflammatory effects unknown